Aroa Biosurgery Limited (ASX: ARX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Aroa Biosurgery Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Aroa Biosurgery Limited (ASX: ARX)
Latest News
Healthcare Shares
Morgans says these small cap ASX healthcare shares are buys with 50% upside
Broker Notes
Buy these 2 ASX health-tech shares that are ready to rocket: Wilson
52-Week Highs
4 ASX All Ordinaries shares hitting new 52-week highs today
52-Week Highs
5 ASX All Ords shares cracking new 52-week highs on Tuesday
52-Week Highs
2 ASX All Ords shares cracking new 52-week highs on Tuesday
Broker Notes
Buy 2 ASX shares for cutting-edge tech changing the world: expert
Healthcare Shares
The ASX All Ords share that's a better, cheaper buy than Polynovo: Wilsons
Share Gainers
Why Aroa Biosurgery, Cettire, Estia Health, and Weebit Nano shares are rising
Growth Shares
3 hot small-cap ASX growth shares Firetrail's backing right now
Broker Notes
Leading brokers name 3 ASX shares to buy today
Healthcare Shares
2 ASX healthcare shares set to explode 70% in 2022: expert
Investing Strategies
This young stock picker bought Afterpay (ASX:APT) at $20. Here's which ASX shares she likes now
Frequently Asked Questions
-
No, Aroa Biosurgery does not pay shareholder dividends at this time.
-
Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.
ARX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Aroa Biosurgery Limited
Aroa Biosurgery Ltd (ASX: ARX) is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.
The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.
